HSC

Researchers developed a proof-of-concept model for delivering gene editing tools to treat blood disorders, allowing for the modification of diseased blood cells directly within the body.

Peter Kurre, MD, seeks to determine to what extent defects in fetal blood forming cells accelerate the loss of bone marrow function in young patients.